Sponsored by
( Note - this is an older article but it just came up again in my news feed and is worth repeating!)
This combination, tested in a small group of newly diagnosed Glioblastoma patients, resulted in an astounding Progression Free Survival rate of 20 months, and the median overall survival was not yet reached. This compares with historical results of 7.2 months PFS for Temodar and Optune.